Changes in Hong Kong stocks | Tongyuankang Pharmaceutical-B (02410) rose by up to 10% TY-9591 tablets to be included in priority review

Zhitongcaijing · 4d ago

The Zhitong Finance App learned that Tongyuankang Pharmaceutical-B (02410) rose by more than 10%. As of press release, it had risen 7.97% to HK$13.95, with a turnover of HK$32.6634 million.

According to the news, on January 6, CDE's official website revealed that edotinib mesylate tablets (TY-9591 tablets) declared by Tongyuankang Pharmaceutical will be included in the priority review for first-line treatment of adult patients with epidermal growth factor receptor (EGFR) exon 19 deficiency (19DEL) or exon 21 (L858R) replacement mutations, accompanied by central nervous system (CNS) metastases. It is worth mentioning that at the World Lung Cancer Conference in September last year, the idotinib tablets released by Tongyuankang Pharmaceutical attracted great attention from peers in a critical phase II clinical trial targeting non-small cell lung cancer brain metastasis.